INTRODUCTION
Erythropoietin is considered to be responsible for control of production of erythrocytes in normal man (1) . Human erythropoiesis, apparently autonomous as respects erythropoietin, has been documented in polycythemia vera in which increased erythropoiesis is observed in the absence of measurable levels, or at least at subnormal Received for publication 7 August 1972 and in revised form 27 October 1972. levels, of erythropoietin (1, 2) . However, in Di Guglielmo's syndrome, the acute leukemia like illness involving erythroid precursors as well as granulocytic precursors, erythropoiesis appears responsive to normal control mechanisms. Correction of anemia by transfusion has resulted in suppression of erythropoiesis (3) (4) (5) (6) (7) and erythropoietin levels (4, 5) . Erythropoietic and erythropoietin suppression by transfusion has been documented in a few patients with "typical" chronic myelocytic leukemia and in idiopathic myelofibrosis with myeloid metaplasia (8) .
The usual terminal event in chronic myelocytic leukemia (CML)1 is development of a myeloblastic phase characterized by gradual increase in immaturity of the granulocytic series of cells and by anemia, thrombocytopenia, consequent infection, hemorrhage, and death. On rare occasions, the "blastic phase" is characterized by erythroblastosis rather than by myeloblastosis (3, 9 megaly, a hemoglobin of 8 g/100 ml, white blood cells (WBC) 35,000/mm3 with neutrophilia, eosinophilia, basophilia, and a plataelet count of 500,000/mm3 were present.
She was treated with busulfan 6 mg/day until November
1970.
We saw her for the first time 2 mo after busulfan had been discontinued. The spleen was palpable 1 cm below the left costal margin, the hematocrit was 27%o mean corpuscular volume (MCV) 115 Am', WBC 4,200/mm3 with 40%o polys, 10%o bands, 20% metamyelocytes, 6% promyelocytes, 3% eosinophils, and platelets were 38,000/mm'. Leukocyte alkaline phosphatase score was 340. A Ph' chromosome was found in 20/20 metaphases on direct culture of marrow. Serum folate was 5.8 ng/100 ml, serum B12 was 900 pg/100 ml and a Schillilng test was normal. Bone marrow biopsy was hypercellular with marked erythroid hyperplasia. Marked megaloblastic changes with numerous multinucleated pronormoblasts and giant megaloblasts were seen in smears of marrow aspirate, and the M: E ratio was 1: 3.
Since the time of study (Table I) In February 1970 she developed fever, weakness and a nonproductive cough. She had had no chemotherapy in the preceding 2 mo. Her temperature was 40'C and the spleen was 5 cm below the left costal margin. The WBC was 37,000/mm3 with 40% polys, 10% myelocytes, 4% promyelocytes, and 4% myeloblasts. Platelets were 260,000/mm8.
Her hematocrit was 30%, MCV was 110 ,um', and there were 10 nucleated red cells per 100 white blood cells. Serum folate was 5.3 ng/100 ml and Bi was greater than 2,000 pg/100 ml. Bone marrow aspirate revealed megaloblastic changes in the erythroid series with multinucleated megaloblasts and bizarre nuclear fragmentation. There were also 23% myeloblasts and promyelocytes. Following completion of the studies shown in Table I , she was treated with a combination of cytosine arabinoside and 6-mercaptopurine, with a return to a picture of CML. During this remission, the red cell morphology was normochromic normocytic wvith normal marrow erythroid maturation.
In early February 1971, she again entered blastic crisis. The hematocrit was 32%, WBC 88,000/mm3 with 41% myeloblasts and promyelocytes; macrocytic red cells and the marrow aspirate revealed megaloblastosis and increased myeloblasts. Despite cytosine arabinoside, 6 mercoptopurine and daunomycin, she deteriorated rapidly and died April 4, 1971 Transfusions were given over a period of 3-4 days and studies were done 8-10 days after the start of transfusions.
RESULTS
Values for hematocrit, reticulocytes, nucleated erythroid precursors in marrow, serum iron, ti of injected radioiron and plasma iron turnover (PIT) before and after transfusion are shown in Table I .
In the first patient with erythroblastic crisis of CML, pretransfusion reticulocytes were slightly increased (upper limit of normal in our laboratory is approximately 100,000/mm3) and the PIT was more than twice normal values (10) . The fast ti of injected iron and a normal serum iron level suggest that the increased PIT reflected an increased rate of erythropoiesis (10) . The discrepancy between the degree of increase in reticulocytes and PIT suggests a significant degree of ineffective erythropoiesis and this was further documented by studying iron incorporation into red cells. Only 18% of injected iron appeared in circulating red cells during 2 wk after iron injection, as compared to a normal value of 80% (10). Ineffective erythropoiesis was also evident in patient E. H. with DiGuglielmo's syndrome in whom red cell utilization of iron did not exceed 45%.
There was little evidence for significant suppression of erythropoiesis by transfusion in either patient with erythroblastic crisis of CML. In L. S., there was a slight reduction in reticulocytes, total percentage of nucleated erythrocytes in marrow and in PIT, but all values remained abnormally high. In B. H. reticulocytes and the percentage of proerythroblasts in marrow (but not total nucleated erythrocytes) increased after transfusion.
Urinary erythropoietin values were studied in L. S. and were appropriate as regards anemia or the lack thereof (1). Base-line excretion before transfusion averaged 12.2 IU/day, while after transfusion erythropoietin was <1IU/day.
In contrast to the two patients with erythroblastic crisis of CML, all three patients with Di Guglielmo's syndrome evidenced suppressed erythropoiesis after transfusion as judged by reticulocytes, percentage of nucleated erythrocytes in marrow, and PIT. DISCUSSION Correction of anemia led to markedly decreased erythropoiesis in the patients with Di Guglielmo's syndrome, as it did in at least seven other patients studied to date (3) (4) (5) (6) (7) . Thus, it would appear that the ineffective, megaloblastic erythropoiesis which characterizes this variant of acute myeloblastic leukemia (12) is subject to normal control mechanisms.
Erythroblastic crisis is a rare terminal event in CML and presents a picture morphologically similar to Di Guglielmo's syndrome (8) , and indeed has been considered as being one form of the syndrome (3). Erythropoiesis was not suppressed significantly by correction of anemia in the two patients with erythroblastic crisis of CML. Thus, it would appear that erythropoiesis in these patients is autonomous as respects normal control mechanisms, as is erythropoiesis in polycythemia vera (1, 2) .
Cytogenetic studies (13) as well as studies of isoenzymes (14) suggest that CML is a clonal disease of pluripotent hematopoietic stem cells. Blastic transformation of CML may represent the emergence of a clone of more severely defective stem cells (13, 15, 16) . There is cytogenetic evidence to suggest that the defect in myeloblastic leukemia can be placed at the same pluripotential cellular level (13) . The pluripotential hematopoietic stem cell has been well characterized in the mouse. Erythrocytes, neutrophils, eosinophils, monocytes, and platelets are derived from this stem cell although in the normal state these compartments may be maintained by more differentiated stem cells, progeny of the pluripotent stem cell (17) .
The nature of the stem cell defect which may lead to leukemia is unknown. However, the defect must confer a growth advantage since leukemic stem cells grow in preference to normal stem cells even though the latter 514.
C identical. Yet, assuming that the abnormal erythroid cells are part of the leukemic process, the former appears to be autonomous as respects erythropoietin while the latter is erythropoietin dependent. These observations suggest that the nature of the stem cell defect differs in diseases of great clinical similarity.
